



SKIN CANCERS

Practical Approaches to Advanced Melanoma Care

Presented by: Douglas B. Johnson, MD, MSCI, *Vanderbilt-Igram Cancer Center*

Overview: Despite recent advances in systemic therapies for advanced melanoma patients, treatment options are at times limited by the availability of reliable molecular markers, development of drug resistance, and patient response or tolerance. This session provides education on current treatment options, when application of these treatments is appropriate, and whether they require administration in a specialized center.

Learning Objectives:

- Identify patients who would significantly benefit from adjuvant or neoadjuvant therapy.
- Discuss tumor-infiltrating lymphocyte treatment benefits, administration requirements, and caveats.

Therapeutic Strategies for Non-Melanoma Skin Cancers

Presented by: Vincent T. Ma, MD, *University of Wisconsin Carbone Cancer Center*

Overview: Current treatment recommendations are limited by risk classification (Basal and Squamous), or by clinical stage (Merkel). While every year further nuances are incorporated into the guidelines to breach the gap between each of these subsets, additional tools are needed for surveillance and therapies after progression on already established treatment options.

Learning Objectives:

- Identify emerging treatment options and determine which eligible patients would benefit from these therapies.
- Discuss timing, utility, and caveats for tumor-informed ctDNA surveillance in patients with Merkel cell carcinoma.

Translating Emerging Therapies into Clinical Practice in Uveal Melanoma Care

Presented by: Arun D. Singh, MD, *Cole Eye Institute and Cleveland Clinic Taussig Cancer Institute*

Overview: Advances have been made in the treatment of liver-directed therapies in patients with uveal melanoma; however, further clinical trials are needed to assess additional treatment options. Additionally, while tebentafusp is an effective treatment option, there are limitations with patient accessibility as it cannot be performed in community settings.

Learning Objectives:

- Discuss current treatment recommendations for uveal melanoma and when surgical management is appropriate.
- Describe advances in liver-directed therapies for patients with hepatic-dominant disease.